Sign in
TerminatedPhase 1/2

APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma

Key facts

Who runs it
Ascentage Pharma Group Inc.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
21 people enrolled
Started
17 Mar 2021
Ended
10 Dec 2024
Type of study
Interventional
Treatments tested
  • APG-1387 for Injection
  • Gemcitabine
  • Nab paclitaxel
Record updated
8 January 2026
Why it stopped
Company Strategy

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Subjects must be ≥18 years of age at time of informed consent
  • Able to comply with the study protocol, in the investigator's judgment
  • Expected survival ≥ 3 months
  • Histology or cytology confirmed as advanced pancreatic adenocarcinoma, and:; Standard treatment failed or intolerant to standard treatment(Phase Ib); First line standard treatment failed (Phase II)
  • ECOG 0-1
  • Adequate organ function
  • Subjects must have at least one measurable lesion evaluated by Computed Tomography (CT) scan on RECIST ver.1.1 at pre-treatment

Who cannot take part

  • Has had chemotherapy, radiation, target or other antitumor therapy within 14 days prior to the first dose of study drug
  • Has received an investigational agent or used an investigational device within 28 days of the first dose of study drug
  • Has received a therapy with TNFα within 28 days of the first dose of study drug
  • Has received IAP-inhibitor before
  • Has had major surgery within 28 days of dosing of investigational agent, or minor surgery within 14 days
  • Patients with clinically evident Hepatitis B surface antigen (HBs) positive, Hepatitis C virus (HCV) antibody positive, Human Immunodeficiency Virus (HIV) antibody positive
  • Known active central nervous system involvement
  • Pregnant or breastfeeding (lactating) women
  • Other situations that investigator think not suit for study

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma. Dose Limiting Toxicities (DLTs) and maximum tolerated dose (MTD) of APG1387 in combination with nab-paclitaxel and gemcitabine will be evaluated in the dose escalation phase Ib. Safety and efficacy of APG1387 plus gemcitabine and nab-paclitaxel will be evaluated in phase II.

The group in the trial

  • APG1387 in combination with Gemcitabine and Nab-PaclitaxelTreatment being tested

    Treatment: APG-1387 for Injection, Gemcitabine, and Nab paclitaxel

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open Label, Multiple Centers Phase Ib/II Study of APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
Publications
Record updated
8 January 2026